As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting articles from the emerging economic regions and publications on COVID-19 and CML.

Read Professor Hughes' CML publications of the month: July 2022

Clinical papers

• A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase - Review
  García-Gutiérrez V et al. J Hematol Oncol, July 2022 – open access publication

• Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
  Haddad FG et al. Am J Hematol, July 2022]

• Exposure-efficacy analysis of Asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic-phase
  Combes FP et al. Clin Pharmacol Ther, July 2022 (epub ahead of print)

• Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor chronic myeloid leukemia patients
  Lipton NJ and Lipton JH. Leuk Lymphoma, July 2022

• Induction-maintenance for the chronic-phase of chronic myeloid leukemia (IMPACT-I): a prospective, single-arm, phase 2 study
  Cheung YM et al. Lancet Oncol, July 2022

• Co-variates associated with outcomes of tyrosine kinase inhibitor therapy in persons with chronic myeloid leukemia initially presenting in accelerated phase
  Yang S et al. Leukemia, July 2022

• Migrating to long-read sequencing for clinical routine BCR-ABL1 TKI resistance mutation screening
  Schaal W et al. Cancer Inform, July 2022 – open access publication

• Treatment of blast phase chronic myeloid leukemia: A rare and challenging entity – Review
  Copland M. Br J Haematol, July 2022 (epub ahead of print)
  – open access publication

• Chronic phase CML with sole P190 (e1a2) BCR:ABL1: long-term outcome among ten consecutive cases
  Abdelmagid MG et al. Blood Cancer J – open access publication

Scientific papers

• RHOA regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
  Zhang H et al. Haematologica, July 2022 (epub ahead of print)
  – open access publication

• Vandetanib drives growth arrest and promotes sensitivity to Imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4
  Ma W et al. Mol Oncol, July 2022 – open access publication

• BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia
  Peter B et al. Am J Hematol, July 2022 (epub ahead of print)
  - open access publication

• Chronic myeloid leukemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype
  Harrington P et al. Br J Haematol, July 2022 (epub ahead of print)
  – open access publication

• Allosteric enhancement of the BCR-ABL1 kinase inhibition activity of Nilotinib by co-binding of Asciminib
  Oruganti B et al. J Biol Chem, July 2022 (epub ahead of print)
  – open access publication

Pediatric papers

• Ponatinib in pediatric patients with Philadelphina chromosome-positive leukemia: a retrospective survey of the Japan Children’s Cancer Group
  Kodama Y et al. Int J Hematol, July 2022
  – open access publication

ERSAP papers

• A ten-year experience of treating chronic myeloid leukemia in rural Rwanda: Outcomes and insights for a changing landscape
  Morgan J et al. JCO Glob Oncol, July 2022
  – open access publication

COVID-19 papers

• COVID-19 in patients with hematologic malignancy
  Langerbeins P and Hallek M. Blood, July 2022
• How I Treat and Prevent COVID-19 in Patients with Hematologic Malignancies and Recipients of Cellular Therapies
  El Chaer,F et al. Blood 2022